van der Heijde D, et al. - In this phase III, 24-month, placebo-controlled Oral Rheumatoid Arthritis (ORAL) Scan trial, investigators examined the effectiveness (including inhibition of structural progression) and safety of tofacitinib in subjects with active rheumatoid arthritis (RA) and ineffectual response to methotrexate (MTX) in 797 individuals. They noted that Boolean remission; and Health Assessment Questionnaire disability index scores were similar between tofacitinib dosages and were maintained from month 12 to 24. They also noted similar type and frequency of safety events for both tofacitinib dosages. These safety events were steady as compared to those reported earlier.